Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P35225
UPID:
IL13_HUMAN
Alternative names:
-
Alternative UPACC:
P35225; O43644; Q4VB52; Q9UDC7
Background:
Interleukin-13 (IL-13) is a pivotal cytokine involved in allergic inflammation and immune responses to parasitic infections. It synergizes with IL2 to regulate interferon-gamma synthesis and stimulates the proliferation and activation of various immune cells. IL-13 plays a crucial role in modulating IL33 activity and antagonizes Th1-driven proinflammatory immune responses, partially through NF-kappa-B suppression.
Therapeutic significance:
Given its central role in allergic rhinitis and its ability to modulate immune responses, targeting IL-13 offers a promising avenue for therapeutic intervention in allergic diseases. Understanding the role of Interleukin-13 could open doors to potential therapeutic strategies.